Inside Innovation

The Biotechnology Innovation Organization (BIO) has released the tenth annual biennial report showcasing employment and economic data of the nation’s biosciences industry. The report highlights

Cajal Neuroscience, a Seattle-based startup, announced a $96 million funding round and released details on its strategy for developing treatments for neurodivergent diseases. The company

Seattle-based biotech HDT Corp. announced a $49 million funding round as part of a government project in partnership with the University of Texas Medical Branch

One Item, a Seattle-area startup, is continuing its partnership with the University of Arkansas for Medical Studies (UAMS), expanding a study of rural Arkansas communities

Cuervo, a Seattle-based vaccine startup, raised $26 million in a funding round with participation from RA Capital Management, Adjuvant Capital, and founding investor GC Biopharma,

At Life Science Washington’s 2022 Medical Device Summit investors, regulatory experts and CEOs shared their expertise and advice on breaking through as an entrepreneur in

Seattle-based biotech Bonum Therapeutics recently announced a $93 million Series A funding round, with participation from Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3×5

Two Washington-based biotechs have made BioSpace’s 2023 Best Places to Work report. Seattle-based Sana Biotechnology has been voted the best place to work in the

The healthcare and life sciences private and public sectors have helped prevent the U.S. from plummeting into a deep recession through commercialization and job creation.

Spokane-based startup Gestalt Diagnostics recently received eight patents in the United Kingdom for its PathFlow software that replaces glass slides and microscopes with data-rich digital

At the 2022 American Society of Nephrology’s Kidney Week, Seattle-based Chinook Therapeutics recently shared data from their Phase I/II trial evaluating BION-1301, a novel anti-APRIL

A Seattle-based startup, Intrinsic Medicine, is merging with Phoenix Biotech Acquisition Corp (PBAX), a special purpose acquisition company or SPAC. The deal is anticipated to